Page last updated: 2024-09-03

3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan and n-acetyltryptophan

3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan has been researched along with n-acetyltryptophan in 1 studies

Compound Research Comparison

Studies
(3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan)
Trials
(3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan)
Recent Studies (post-2010)
(3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan)
Studies
(n-acetyltryptophan)
Trials
(n-acetyltryptophan)
Recent Studies (post-2010) (n-acetyltryptophan)
7502490131

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Corrigan, F; Hassall, MM; Thornton, E; Vink, R1

Other Studies

1 other study(ies) available for 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan and n-acetyltryptophan

ArticleYear
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:5

    Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase

2014